DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for placental site trophoblastic tumor — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePlacental site trophoblastic tumor maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for placental site trophoblastic tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ras homolog family member A (RHOA) — RHOA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5C4M · 1.3 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Placental site trophoblastic tumor is a rare gestational trophoblastic disease; three quarters of cases follow a normal pregnancy. A 2006 report notes a 10 to 20% mortality rate when not treated properly and describes a case with metastases to the left adrenal gland and both lungs. A 2009 case describes a 47-year-old woman with one year of amenorrhea and cough who was found to have diffuse pulmonary metastases 12 years after her most recent pregnancy; those metastases were nonhypermetabolic on PET scan, and the authors suggest the slow growth rate of the tumor may explain the lack of PET findings, contrasting with earlier reports.
A 2000 report describes a patient with metastatic PSTT who was free of disease more than five years after diagnosis after receiving multimodality treatment including surgery, chemotherapy, and radiotherapy. That same report reviews 23 additional cases from the literature with differing treatments and lengths of survival; eleven other patients survived from 12 to 36 months after initial diagnosis. The authors conclude that metastatic PSTT has a poor prognosis and requires aggressive treatment.
No abstract reports a controlled trial, a standard chemotherapy regimen, or a molecular target for this disease. The published evidence consists entirely of case reports and small case series. What is missing is any prospective trial, any systematic collection of treatment outcomes across centres, any biomarker to stratify patients by risk, and any funding mechanism to study a tumor too rare for conventional drug development.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2006 · 6 citations
Placental site trophoblastic tumor (PSTT) with metastases to lungs and adrenal glands.
AbstractPlacental site trophoblastic tumor (PSTT) is a rare type of gestational trophoblastic disease and three quarters of cases follow a normal pregnancy. Metastases are very rare but when present are often widespread. It has 10 to 20% mortality rate when not treated properly. We present report of a case of placental site trophoblastic tumor with metastases to left adrenal gland and both lungs.
Diagnostic Evaluation of Metastatic Placental Site Trophoblastic Tumor
AbstractIn Brief BACKGROUND: Placental site trophoblastic tumor, a type of gestational trophoblastic disease, is a rare tumor composed of intermediate trophoblasts. CASE: We report the case of a 47-year-old woman with 1 year of amenorrhea who presented with cough in the absence of gynecologic symptoms. She was found to have diffuse pulmonary metastases that were nonhypermetabolic on positron emission tomography (PET) scan. She was diagnosed with Stage 3 metastatic placental site trophoblastic tumor 12 years after her most recent pregnancy. CONCLUSION: Placental site trophoblastic tumor is an unusual malignancy that may present remotely from antecedent gestational events. The relatively slow growth rate of this tumor may explain the lack of PET findings in our case. Metastatic placental site trophoblastic tumor may not be hypermetabolic on positron emission tomography, in contrast to previously published reports.
Lower Genital Tract Metastases of Placental Site Trophoblastic Tumor: Case Report and Review of the Literature
AbstractObjectives. We present a case of metastatic placental site trophoblastic tumor (PSTT) and review the English literature on this entity. Materials and Methods. In addition to the case presentation, literature review describes 23 additional cases with differing treatments and length of survival. Results. The patient is free of disease more than 5 years after diagnosis. She received multimodality treatment including surgery, chemotherapy, and radiotherapy. Eleven other patients survived the disease from 12 to 36 months after initial diagnosis. Conclusion. Metastatic PSTT has a poor prognosis and requires aggressive treatment. ▪
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
